Linifanib (ABT-869) |cas 796967-16-3 |DC Chemicals|Supplier|Price|Buy  

Linifanib (ABT-869)  |cas 796967-16-3 |DC Chemicals|Supplier|Price|Buy

DC Chemicals Supply: Linifanib (ABT-869)  ,cas 796967-16-3, Cat No. DC4231, In stock

Contact: website: www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642766；

Product name: Linifanib (ABT-869), Synonym:　ABT869,Linifanib (ABT 869), Cat No. DC4231, Cas: 796967-16-3, Chemical Name:N/A, Molecular Formula: C21H18FN5O, MW: 375.405

Linifanib (ABT-869) Cas#796967-16-3.Purity:99%.Best Price and Quality in the Market!Supplied by DC Chemicals! ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families (e.g., KDR, Flt1, Flt3, Flt4, CSF-1R, and KIT) demonstrating IC50 values ranging from 4-190 nM.1 ABT-869 shows little activity against unrelated RTKs, cytoplasmic tyrosine kinases, or Ser/Thr kinases (IC50s > 1 μM).ABT-869 inhibits proliferation in MV-4-11 and MOLM-13 cells (acute myeloid leukemia cell lines harboring RTK mutations; IC50s = 4 and 6 nM, respectively), inducing apoptosis as evidenced by an increased sub-G0/G1 phase cell population, caspase activation, and PARP cleavage.In murine xenograft models, as well as in a phase 1 clinical trial, ABT-869 demonstrated respectable efficacy in solid tumors including lung and hepatocellular carcinomas.

For the detailed information about the solubility of Linifanib (ABT-869)  in water, the solubility of Linifanib (ABT-869)  in DMSO, the solubility of Linifanib (ABT-869)  in PBS buffer, the animal experiment of Linifanib (ABT-869) ,the in vivo and in vitro test of Linifanib (ABT-869) ,the cell experiment of Linifanib (ABT-869) ,the IC50 and EC50 of Linifanib (ABT-869) please contact DC Chemicals.